Clinical Trial Update: A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating the safety and tolerability of CVL-231 (emraclidine) in adults with schizophreni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CVL-231 (Emraclidine) (emraclidine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED